id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-0691-0013,FDA,FDA-2021-D-0691,Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 or Programmed Cell Death-Ligand 1 Blocking Antibodies for Treatment of Patients With Cancer; Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-06T05:00:00Z,2022,12,2022-12-06T05:00:00Z,,2022-12-06T13:06:58Z,2022-26464,0,0,090000648551cdc8
FDA-2021-D-0691-0014,FDA,FDA-2021-D-0691,"Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer
Guidance for Industry - Final Guidance",Other,Guidance,2022-12-06T05:00:00Z,2022,12,2022-12-06T05:00:00Z,,2024-11-07T00:44:34Z,,1,0,090000648550fc17